Skip to content
  • Contact
  • Early Detection
    • Pancreatic Cancer
      • Genetic Predisposition & Family History
      • Newly Diagnosed Type 2 Diabetes
    • Ovarian Cancer
  • Tests
    • Avantect Pancreatic Cancer Test
    • Avantect Ovarian Cancer Test
  • For Providers
    • Using Avantect
    • Publications
    • FAQs
  • For Patients
    • Patient Access
    • Blood Draw
    • Patient FAQs
    • Pancreatic Cancer Patient Blog
  • Contact
  • Billing & Reimbursement
  • Order Test
  • Early Detection
    • Pancreatic Cancer
      • Genetic Predisposition & Family History
      • Newly Diagnosed Type 2 Diabetes
    • Ovarian Cancer
  • Tests
    • Avantect Pancreatic Cancer Test
    • Avantect Ovarian Cancer Test
  • For Providers
    • Using Avantect
    • Publications
    • FAQs
  • For Patients
    • Patient Access
    • Blood Draw
    • Patient FAQs
    • Pancreatic Cancer Patient Blog
  • Contact
  • Billing & Reimbursement
  • Order Test

Day: July 7, 2023

Understanding The Limitations of CA19-9 As A Biomarker for Pancreatic Cancer Testing

Avantect pancreatic cancer test technology

Among the tools available for pancreatic cancer testing, the biomarker CA19-9 has gained attention for its potential role in monitoring and diagnosis of the disease. In this blog post, we’ll explore what CA19-9 is, how it is used in pancreatic cancer testing, and its limitations as a biomarker. 

ClearNote Health logo in white

© 2025 ClearNote Health. All rights reserved.
Avantect is a trademark of ClearNote Health. Other trademarks are the property of their respective owner.

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Early Detection
    • Pancreatic Cancer
      • Genetic Predisposition & Family History
      • Newly Diagnosed Type 2 Diabetes
    • Ovarian Cancer
  • Tests
    • Avantect Pancreatic Cancer Test
    • Avantect Ovarian Cancer Test
  • For Providers
    • Using Avantect
    • Publications
    • FAQs
  • For Patients
    • Patient Access
    • Blood Draw
    • Patient FAQs
    • Pancreatic Cancer Patient Blog
  • Contact
  • Billing & Reimbursement
  • Order Test
  • Early Detection
    • Pancreatic Cancer
      • Genetic Predisposition & Family History
      • Newly Diagnosed Type 2 Diabetes
    • Ovarian Cancer
  • Tests
    • Avantect Pancreatic Cancer Test
    • Avantect Ovarian Cancer Test
  • For Providers
    • Using Avantect
    • Publications
    • FAQs
  • For Patients
    • Patient Access
    • Blood Draw
    • Patient FAQs
    • Pancreatic Cancer Patient Blog
  • Contact
  • Billing & Reimbursement
  • Order Test

Important information

The Avantect Pancreatic and Ovarian Cancer Tests are early detection tests. The tests do not establish a diagnosis of pancreatic or ovarian cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic or ovarian cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic or ovarian cancers will be detected. Some patients with pancreatic or ovarian cancer may have a “Pancreatic/Ovarian Cancer Signal not detected” result. Some patients without pancreatic or ovarian cancer may have a “Pancreatic/Ovarian Cancer Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no pancreatic or ovarian cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost. 

The tests were developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and have not been cleared or approved by the US Food and Drug Administration (FDA).